Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.

Ying-Tao LinYing ChenTian-Xiu LiuFang KuangPing Huang

Published in: Cancer management and research (2021)

Camrelizumab is a cost-effective option compared with docetaxel or irinotecan chemotherapy in patients with advanced ESCC as second-line therapy in China.

Keyphrases

locally advanced
squamous cell carcinoma
rectal cancer
radiation therapy
small cell lung cancer
stem cells
chemotherapy induced